Abstract
Background: Patients with diabetes usually exhibit diabetic dyslipidaemia.
Aim: The aim of the review is to present the quantitative and qualitative alterations of lipids and lipoproteins and the associated mechanisms in patients with diabetic dyslipidaemia.
Results: The main quantitative changes observed in patients with diabetic dyslipidaemia are increased triglycerides and decreased high-density lipoprotein (HDL) cholesterol levels. Qualitative abnormalities mainly include increased small dense low-density lipoprotein (LDL) particles (despite similar serum LDL cholesterol levels as non-diabetic subjects) and alterations in the apolipoprotein content of HDL particles. Alterations in the activities of enzymes involved in lipoprotein metabolism, such as cholesteryl ester transfer protein, and the lipoprotein content of lipid particles, along with their glycation and oxidation, play a role in the pathogenesis of diabetic dyslipidaemia.
Conclusion: Diabetic dyslipidaemia is associated with quantitative and qualitative alterations of lipids and lipoproteins, which are associated with increased cardiovascular risk.
Keywords: Diabetes, dyslipidaemia, atherosclerosis, apolipoprotein, triglycerides, high-density lipoprotein.
Graphical Abstract
Current Vascular Pharmacology
Title:Pathophysiology of Diabetic Dyslipidaemia
Volume: 15 Issue: 6
Author(s): Theodosios Filippatos, Vasilios Tsimihodimos, Eleni Pappa and Moses Elisaf*
Affiliation:
- Department of Internal Medicine, School of Medicine, University of Ioannina, 451 10 Ioannina,Greece
Keywords: Diabetes, dyslipidaemia, atherosclerosis, apolipoprotein, triglycerides, high-density lipoprotein.
Abstract: Background: Patients with diabetes usually exhibit diabetic dyslipidaemia.
Aim: The aim of the review is to present the quantitative and qualitative alterations of lipids and lipoproteins and the associated mechanisms in patients with diabetic dyslipidaemia.
Results: The main quantitative changes observed in patients with diabetic dyslipidaemia are increased triglycerides and decreased high-density lipoprotein (HDL) cholesterol levels. Qualitative abnormalities mainly include increased small dense low-density lipoprotein (LDL) particles (despite similar serum LDL cholesterol levels as non-diabetic subjects) and alterations in the apolipoprotein content of HDL particles. Alterations in the activities of enzymes involved in lipoprotein metabolism, such as cholesteryl ester transfer protein, and the lipoprotein content of lipid particles, along with their glycation and oxidation, play a role in the pathogenesis of diabetic dyslipidaemia.
Conclusion: Diabetic dyslipidaemia is associated with quantitative and qualitative alterations of lipids and lipoproteins, which are associated with increased cardiovascular risk.
Export Options
About this article
Cite this article as:
Filippatos Theodosios, Tsimihodimos Vasilios, Pappa Eleni and Elisaf Moses*, Pathophysiology of Diabetic Dyslipidaemia, Current Vascular Pharmacology 2017; 15 (6) . https://dx.doi.org/10.2174/1570161115666170201105425
DOI https://dx.doi.org/10.2174/1570161115666170201105425 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Reducing the Risk of Major Elective Non-cardiac Surgery: Is there a Role for Levosimendan in the Preoperative Optimization of Cardiac Function?
Current Drug Targets Endothelial Dysfunction: The Link Between Homocysteine and Hydrogen Sulfide
Current Medicinal Chemistry Organophosphorus Compounds: Intervention in Mechanisms of Signal Transduction Relevant to Proliferative, Immunological and Circulatory Disorders
Current Medicinal Chemistry Coronary CT Angiography in the Diagnosis of Coronary Artery Disease
Current Medical Imaging Beyond Cholesterol Lowering: Pleiotropic Effects of Bile Acid Binding Resins Against Cardiovascular Disease Risk Factors in Patients with Metabolic Syndrome
Current Vascular Pharmacology Effects of Statins on Bone Markers, Bone Mineral Density and Fractures. Possible Role in Osteoporosis Treatment
Current Pharmaceutical Analysis Flavonoids and Chagas' Disease: The Story So Far!
Current Topics in Medicinal Chemistry Chemokines and Atherosclerotic Plaque Progression: Towards Therapeutic Targeting?
Current Pharmaceutical Design PCSK9 Inhibitors and Cardiovascular Disease: Impact on Cardiovascular Outcomes
Current Drug Discovery Technologies Combining “Omics” Strategies to Analyze the Biotechnological Potential of Complex Microbial Environments
Current Protein & Peptide Science Synthesis of New A-CD Estrogenic Compounds: D-Homo-analogs Lacking B-ring
Current Organic Chemistry New Approaches for the Treatment of Chagas Disease
Current Drug Targets Outcomes of Patients with Chronic Heart Failure and Iron Deficiency Treated with Intravenous Iron: A Meta-analysis
Cardiovascular & Hematological Disorders-Drug Targets Editorial: Nanotechnology: Past, Present and Future Trends
Current Nanomedicine Synthetic Aspects and First-time Assessment of 2-amino-1,3-selenazoles Against Mycobacterium tuberculosis
Letters in Drug Design & Discovery Excess Exposure to Insulin Is the Primary Cause of Insulin Resistance and its Associated Atherosclerosis
Current Molecular Pharmacology Clinical, Molecular- and Cytogenetic Analysis of a Case of Severe Radio- Sensitivity
Current Genomics Mitochondrial Mutations in Atherosclerosis: New Solutions in Research and Possible Clinical Applications
Current Pharmaceutical Design The GH/IGF-1 Axis and Heart Failure
Current Cardiology Reviews Ketamine as Antidepressant? Current State and Future Perspectives
Current Neuropharmacology